<DOC>
	<DOCNO>NCT01932437</DOCNO>
	<brief_summary>This study evaluate safety local tolerability single intramuscular ( IM ) dose ETI-204 ; evaluate pharmacokinetics ( PK ) single IM dose ETI-204 ; evaluate immunogenicity single IM dose ETI-204 .</brief_summary>
	<brief_title>Safety , Tolerability , PK Single IM Doses ETI-204 Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Anthrax</mesh_term>
	<criteria>1 . Females male ≥18 year age ; 2 . All female regardless childbearing potential must negative serum beta human chorionic gonadotropin ( βhCG ) pregnancy test Screening Day 1 ; 3 . Females childbearing potential ( i.e. , postmenopausal surgically sterile ) must agree practice abstinence use medically accept method contraception time Screening 30 day final study visit . Acceptable method contraception include diaphragm/cervical cap spermicide ; sponge spermicide ; condom spermicide ; intrauterine device condom spermicide . The following contraceptive method acceptable used condom spermicide : birth control pill , birth control patch , vaginal ring , hormone skin , hormone injection ; 4 . Postmenopausal female , define female amenorrhea least 12 month either naturally follow cessation exogenous hormonal treatment , follicle stimulate hormone level &gt; 40 mIU/mL Screening ; 5 . Females undergone surgical sterilization , include hysterectomy , bilateral oophorectomy , bilateral salpingectomy , tubal ligation , tubal essure ; 6 . Males must agree practice abstinence use condom spermicide refrain sperm donation Screening study 30 day final study visit ; 7 . Provide write informed consent ; 8 . Willing comply study restriction . 1 . Body weight &gt; 100 kg ; 2 . Body mass index ≥32 kg/m2 ; 3 . Pregnant lactate female ; 4 . Clinically significant comorbidity would interfere completion study procedures objective , compromise subject 's safety ; 5 . Supine systolic blood pressure ( BP ) ≥150 mmHg ≤90 mmHg diastolic BP ≥95 mmHg ; 6 . Use H1 receptor antagonist ( i.e. , antihistamine ) within 5 day prior Day 1 ; 7 . Evidence drug alcohol abuse within 6 month Day 1 determine Investigator ; 8 . Positive test result drug abuse ( exception medically prescribed drug ) Screening Day 1 ; 9 . Positive test alcohol Screening , subject Investigator 's discretion . Subjects test positive alcohol Day 1 exclude study ; 10 . Treatment investigational agent within 30 day 5 halflives investigational agent Day 1 ( whichever longer ) ; 11 . Congenital acquire immunodeficiency syndrome ; 12 . Prior solid organ bone marrow transplant ; 13 . Positive test Hepatitis B ( surface antigen ) , Hepatitis C , human immunodeficiency virus ( HIV ) Screening ; 14 . History prior treatment anthrax exposure prior anthrax infection ; 15 . Prior immunization approve investigational anthrax vaccine prior treatment investigational anthrax treatment ( e.g. , ETI204 , raxibacumab , anthrax immune globulin ) ; 16 . Military personnel deploy 1990 , unless subject provide documentation demonstrate previously receive approved investigational anthrax vaccine ; 17 . Use systemic steroid , immunosuppressive agent , anticoagulant , antiarrhythmic within 1 year prior Day 1 . A single short course ( i.e. , less 14 day ) systemic steroid therapy allow , provide conclude 6 month prior Day 1 ; 18 . Donation loss &gt; 500 mL blood within 30 day plasma within 7 day Day 1 ; 19 . Prior stroke , epilepsy , relapse degenerative central nervous system disease , relapse degenerative ocular disease ; 20 . Myocardial infarction acute coronary syndrome past 5 year , active angina pectoris , heart failure ( New York Heart Association scale &gt; 1 ) ; 21 . History chronic liver disease ; 22 . Calculated creatinine clearance &lt; 30 mL/min use CockcroftGault equation ; 23 . Any clinically significant abnormality , Investigator 's opinion , electrocardiogram ( ECG ) clinical laboratory test ( hematology , clinical chemistry , urinalysis ) Screening . Out range test may repeat confirm ; 24 . History allergic hypersensitivity reaction hive therapeutic antibody immunoglobulins ; 25 . History malignant neoplasm within last 5 year , exception adequately treat localized situ nonmelanoma carcinoma skin ( e.g. , basal cell carcinoma ) cervix ; 26 . Subjects , opinion Investigator , suitable candidate enrollment may comply requirement study . 27 . Platelet count &lt; 140 K/µL ; 28 . Prothrombin time/international normalize ratio activate partial thromboplastin time &gt; 1.2 X upper limit normal Screening Day 1 ; 29 . Poor muscle mass determine Investigator ; 30 . Family personal history bleed disorder ; 31 . History unexplained bleeding ; 32 . Use anticoagulant antiplatelet drug 3 month prior Screening . At discretion Investigator , daily aspirin may take general health reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>